Samsung Medical Center
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Subsidiary
- Established
- 1994-01-01
- Employees
- 501
- Market Cap
- -
Phase II Study of Carfilzomib, Pomalidomide, and Dexamethasone for Myeloma Patients Who Had Relapsed or Progressed After Carfilzomib, Lenalidomide, and Dexamethasone
Phase 2
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2022-08-22
- Last Posted Date
- 2022-08-22
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 33
- Registration Number
- NCT05509374
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Carfilzomib, Lenalidomide, and Dexamethasone Re-induction Followed by the 2nd ASCT in Multiple Myeloma Patients Relapsed After the 1st ASCT
- First Posted Date
- 2022-08-11
- Last Posted Date
- 2022-08-12
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 58
- Registration Number
- NCT05497102
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
The Prognostic Role and Diagnostic Efficacy of Exercise Right Heart Catheterization With a Simultaneous Echocardiography in Patients With Dyspnea on Exertion
Recruiting
- Conditions
- Heart Failure With Preserved Ejection FractionChronic Pulmonary Thromboembolism (Disorder)
- Interventions
- Diagnostic Test: Exercise hemodynamic test
- First Posted Date
- 2022-08-08
- Last Posted Date
- 2022-08-08
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 400
- Registration Number
- NCT05490901
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Atorvastatin Use and Portal Hypertension in Patients With Hepatitis B Virus-related Liver Cirrhosis: A Randomized Controlled Trial
Phase 2
Not yet recruiting
- Conditions
- Portal HypertensionHepatitis B
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-08-02
- Last Posted Date
- 2022-08-02
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 36
- Registration Number
- NCT05483894
Hypofractionated IMRT With Concurrent Chemotherapy in Muscle-invasive Bladder Cancer (HIRACUM)
Not Applicable
Recruiting
- Conditions
- Bladder Cancer
- Interventions
- Radiation: hypo-IMRT
- First Posted Date
- 2022-07-12
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 53
- Registration Number
- NCT05453682
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Effectiveness of AR in Ventilator Setting Education.
Not Applicable
Completed
- Conditions
- Nursing Education
- Interventions
- Device: AR guidance with Hololens 2
- First Posted Date
- 2022-07-07
- Last Posted Date
- 2022-07-07
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT05446896
- Locations
- 🇰🇷
Samsung Medical Centre, Seoul, Korea, Republic of
GENOSS Coronary Stent Clinical Trial
Not Applicable
Recruiting
- Conditions
- Ischemic Heart Disease
- Interventions
- Device: Implanatation of Xience DES everolimus-eluting coronary systemDevice: Implanatation of Genoss DES sirolimus-eluting coronary system
- First Posted Date
- 2022-07-06
- Last Posted Date
- 2022-07-06
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 850
- Registration Number
- NCT05444452
- Locations
- 🇰🇷
Cardiac and Vascular Center; Samsung Medical Center, Seoul, Korea, Republic of
Pilot Study of Antiviral Treatment in Combination With Low-dose Gemcitabine in EBV-associated Gastric Cancer (EBVaGC)
Not Applicable
Withdrawn
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2022-06-24
- Last Posted Date
- 2022-11-01
- Lead Sponsor
- Samsung Medical Center
- Registration Number
- NCT05431244
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
A Study on Telemedicine Applied to Actual Outpatient Clinic for Epilepsy
Completed
- Conditions
- Epilepsy
- Interventions
- Other: (exposure) telemedicine
- First Posted Date
- 2022-06-14
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 307
- Registration Number
- NCT05418257
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Gangnam-go, Korea, Republic of
Lazertinib Real-world Observational Study of in Pre-treated EGFR T790M Mutant With Advanced Non-small Cell Lung Cancer
- Conditions
- Metastatic Lung Non-Small Cell CarcinomaEGFR T790M
- Interventions
- First Posted Date
- 2022-05-17
- Last Posted Date
- 2022-05-19
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 900
- Registration Number
- NCT05377788
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath